PD L1 News and Research

RSS

AI-Powered Drug Breakthrough: Insilico Unveils Potent FGFR2/3 Inhibitor for Solid Tumors

Insilico Medicine, a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

29 Dec 2023

Study Reveals an Immunological Strategy to Overcome Microbiome-Related Immunotherapy Resistance

Cancer immunotherapy has transformed the treatment of many types of cancer. Yet, for reasons that remain poorly understood, not all patients get the same benefit from these powerful therapies.

4 May 2023

Identifying Lung Cancer Patients Who May Not Respond Well to Immunotherapy by MYC Gene Activation

Lung cancer patients who may not react well to immunotherapy (ICB) could be identified by the oncogenic activation of MYC, an important gene in the development of cancer.

17 Apr 2023

Additional therapeutic maneuver may be needed to stop some metastasized tumors Cancer That...

Cancer that has spread to areas like the lungs can apply the brakes to a natural pathway that should recruit killer T cells directly to where it has metastasized, scientists report.

29 Mar 2023

Keeping lymph nodes in the body can boost the efficacy of cancer immunotherapy

Cancer treatment routinely involves taking out lymph nodes near the tumor in case they contain metastatic cancer cells.

21 Mar 2023

Iron-dependent cell death can be used to improve immunotherapies against liver cancer

Iron-dependent cell death (ferroptosis) is a type of programmed cell death by means of which the body kills off diseased, defective or superfluous cells.

20 Feb 2023

Strata Oncology publishes study validating integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).

8 Feb 2023

AI-based strategy helps discover high-affinity antibody drugs

Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.

31 Jan 2023

Researchers report the identification of novel small molecules that stimulate human adaptive immune responses

An antibody that is successfully used to treat a variety of tumors has been replaced with a tiny molecule that researchers from Tel Aviv University and the University of Lisbon have jointly found and manufactured.

9 Aug 2022

Giving attention to beta cells instead of the immune system could be a chance to prevent type 1 diabetes

Research studying the autoimmune response, in which the immune system kills the insulin-producing pancreatic islet beta cells, is a common topic of type 1 diabetes research.

1 Jul 2022

Lipid nanoparticles successfully stopped the emergence and development of tumors cells, a new study reveals

UT Southwestern researchers have developed nanoparticles that can penetrate the physical barriers that surround tumors and reach cancer cells.

27 Jun 2022

Vitamin E can reinvigorate dendritic cells to enhance immunotherapy responses

Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance immunotherapy responses by stimulating the activity of dendritic cells in the tumor.

18 Apr 2022

Spatial maps offer insights into the battle between melanoma cells and immune cells

Melanoma is a somewhat unusual cancer-;one that blooms before our very eyes, often on sun-exposed skin, and can quickly become deadly as it turns our own skin against us and spreads to other organs.

From Harvard Medical School 15 Apr 2022

Single-cell spatial analysis may provide information about neoadjuvant therapy for triple-negative breast cancer

A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab (Tecentriq) to chemotherapy as neoadjuvant treatment for patients with early high-risk and locally advanced triple negative breast cancer (TNBC), according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.

8 Dec 2021

New strategy to improve the therapeutic efficacy of liver cancer immunotherapy

In recent years, tumor immunotherapy has emerged as a highly promising and much-touted oncological approach.

8 Dec 2021

New model for early prediction of cancer patients' response to immunotherapy

Researchers have developed a model that could predict early on in treatment whether cancer patients will respond to immunotherapy, according to a report published today in eLife.

10 Nov 2021

New technology efficiently delivers immune checkpoint inhibitors for treating brain tumors

Multi-institutional researchers have succeeded in efficiently delivering an immune checkpoint inhibitor (ICI) into the mouse brain, confirming its high efficacy and specificity in treating orthotopically transplanted mice with glioblastoma (GBM). The research was published in Nature Biomedical Engineering.

12 Oct 2021

Scientists devise a strategy to enhance anti-tumor immunity

A synthetic molecular code exhibits the potential of enhancing the response of certain cancer patients to immunotherapy treatments.

15 Sep 2021

Research provides a detailed 'proteogenomic' view of lung squamous cell carcinoma

Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung squamous cell carcinoma (LSCC) has largely come up short.

6 Aug 2021

Study: Biomarker can predict response to immunotherapies in breast cancer patients

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

28 Jul 2021